Global Burden of Disease
Psoriasis is a chronic, non-contagious, painful, and disabling disease for which there is no cure and with negative impact on patients’ quality of life (QoL). It can occur at any age and is most common in the age group 50–69.
125 million people worldwide or 2-4 percent of the total population have psoriasis, according to the World Psoriasis Day consortium. More than 85% of patients receiving treatment use topical drugs and according to the National Psoriasis Foundation (NPF), itch is present in between 70 % and 90 % of psoriasis patients. Together with flaking and scaling, itching is the most burdensome symptom to patients. In addition, people living with psoriatic disease are at an elevated risk of developing other chronic and serious health conditions, including arthritis, cardiovascular diseases, metabolic syndrome, inflammatory bowel disease and depression.
The total cost of psoriasis in the US is estimated to be around $35.2 billion, with $12.2 billion in incremental medical costs.
The number of people in the US and EU living with psoriasis is estimated to be around 15 million people.
For many reasons, psoriasis can be psychologically devastating. Patients’ lives become especially difficult when psoriasis is present in highly visible areas of the skin such as the face and hands.
Current treatment options include topicals, orals and biologics depending on severity and if Psoriatic Arthritis (PSA) is present. According to the National Psoriasis Foundation, psoriasis is defined as Mild (<3% body surface area “BSA” covered), Moderate (3%-10% BSA), or Severe (>10% BSA).
Approximately 80% of patients with psoriasis can sufficiently be treated with topical therapies due to the disease being localized skin issues and most patients on systemic therapies also use topicals for spot treatment.
Studies show that poor adherence has historically been a major problem in topical therapies resulting in suboptimal treatment effect in real world settings. Main reasons are that people find many conventional topicals greasy or difficult to apply or that they cause skin irritation.
In the pursuit of developing topicals that have fast onset and high efficacy topicals have often been compromised on tolerability, safety, or convenience of use in daily routines.
Addressing adherence in combination with tolerable, fast and high efficacy is an important unmet need in the plaque psoriasis market.
To address this unmet need, MC2 Therapeutics is applying its PAD Technology™ to incorporate all three essentials in one product solution for the benefit of patients living with plaque psoriasis.
Psoriasis Treatment guidelines:
For further information on selected treatment guidelines, please visit below links:
MC2 Therapeutics is a proud partner of the National Psoriasis Foundation (NPF). Please visit their website below for more information on psoriasis: